StockNews.com Lowers Becton, Dickinson and (NYSE:BDX) to Hold

StockNews.com lowered shares of Becton, Dickinson and (NYSE:BDXGet Rating) from a buy rating to a hold rating in a research note released on Friday.

Several other equities analysts have also recently issued reports on the company. Bank of America started coverage on Becton, Dickinson and in a research report on Tuesday, March 1st. They set a neutral rating on the stock. Piper Sandler decreased their price target on Becton, Dickinson and from $265.00 to $255.00 in a research note on Thursday, May 5th. Argus boosted their price target on Becton, Dickinson and from $275.00 to $310.00 in a research note on Monday, February 28th. Morgan Stanley boosted their price target on Becton, Dickinson and from $293.00 to $295.00 and gave the stock an overweight rating in a research note on Monday, April 11th. Finally, SVB Leerink boosted their price target on Becton, Dickinson and from $270.00 to $275.00 and gave the stock a market perform rating in a research note on Friday, February 4th. Seven research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of Hold and an average target price of $275.63.

NYSE BDX opened at $252.20 on Friday. The company has a current ratio of 1.53, a quick ratio of 0.78 and a debt-to-equity ratio of 0.72. The business’s 50 day moving average is $263.02 and its two-hundred day moving average is $257.33. Becton, Dickinson and has a 12-month low of $235.13 and a 12-month high of $280.62. The stock has a market capitalization of $71.82 billion, a price-to-earnings ratio of 39.78, a PEG ratio of 3.19 and a beta of 0.64.

Becton, Dickinson and (NYSE:BDXGet Rating) last released its earnings results on Thursday, May 5th. The medical instruments supplier reported $3.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.99 by $0.19. Becton, Dickinson and had a return on equity of 14.91% and a net margin of 9.59%. The company had revenue of $5.01 billion for the quarter, compared to analysts’ expectations of $4.78 billion. During the same quarter in the previous year, the firm posted $3.19 EPS. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. Equities analysts forecast that Becton, Dickinson and will post 12.74 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 30th. Investors of record on Thursday, June 9th will be paid a $0.87 dividend. This represents a $3.48 dividend on an annualized basis and a yield of 1.38%. Becton, Dickinson and’s payout ratio is currently 54.89%.

In related news, EVP Betty D. Larson sold 14,374 shares of the company’s stock in a transaction that occurred on Friday, February 25th. The stock was sold at an average price of $271.90, for a total value of $3,908,290.60. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.50% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. raised its holdings in Becton, Dickinson and by 4.2% in the 4th quarter. BlackRock Inc. now owns 20,694,679 shares of the medical instruments supplier’s stock valued at $5,204,300,000 after acquiring an additional 828,789 shares during the last quarter. Wellington Management Group LLP raised its holdings in Becton, Dickinson and by 6.1% in the 3rd quarter. Wellington Management Group LLP now owns 14,489,749 shares of the medical instruments supplier’s stock valued at $3,561,871,000 after acquiring an additional 837,802 shares during the last quarter. State Street Corp raised its holdings in Becton, Dickinson and by 3.9% in the 4th quarter. State Street Corp now owns 12,705,205 shares of the medical instruments supplier’s stock valued at $3,195,105,000 after acquiring an additional 480,684 shares during the last quarter. Morgan Stanley raised its holdings in Becton, Dickinson and by 7.1% in the 3rd quarter. Morgan Stanley now owns 9,827,875 shares of the medical instruments supplier’s stock valued at $2,415,888,000 after acquiring an additional 652,875 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in Becton, Dickinson and by 8.3% in the 4th quarter. JPMorgan Chase & Co. now owns 5,048,607 shares of the medical instruments supplier’s stock valued at $1,269,624,000 after acquiring an additional 388,758 shares during the last quarter. Institutional investors own 86.58% of the company’s stock.

About Becton, Dickinson and (Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Read More

Analyst Recommendations for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.